Future of Cancer Diagnostics Market: Growth Opportunities and Business Expansion Strategies

Dec. 6, 2011 - PRLog -- Venture Planning Group (www.VPGMarketResearch.com), an international publishing and management consulting firm, is pleased to add a new report to its collection of Diagnostics Market Research and Technology Assessment publications.

"Future of Cancer Diagnostics Market: Growth Opportunities and Business Expansion Strategies" (http://www.vpgmarketresearch.com/cancer.html)
is a seven-country, 1200-page report designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the cancer diagnostics market during this decade.

To review or order this report, visit http://www.vpgmarketresearch.com/the-cancer-diagnostics-market.html

Contact

Robert Fisher
Healthcare Research
robert@vpgcorp.com
+1 212 564 2838
http://www.VPGMarketResearch.com

Highlights

- Identifies and evaluates major business opportunities emerging in the cancer diagnostics market
- Examines trends in the U.S., Europe and Japan
- Reviews current and emerging cancer diagnostic tests
- Analyzes applications of emerging diagnostic technologies
- Forecasts sales of major cancer diagnostic tests by country and market segment
- Profiles leading market players and potential entrants
- Suggests alternative business expansion strategies for suppliers.

Geographic Coverage

- France
- Germany
- Italy
- Japan
- Spain
- UK
- USA

Market Segmentation Analysis

- Sales and market shares of major suppliers, by individual test
and country.

- Ten-year test volume and sales forecasts for major
cancer diagnostic tests by country and market segment,
including:

- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers

- Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers
by country.

- Cancer statistics, etiology and recent developments in the
U.S., Japan and five major European countries.

Current and Emerging Products

- Review of over 200 current and emerging cancer diagnostic tests,
including:

- Biochemical Markers
- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

- Review of major analyzers used for
cancer diagnostic testing, including their operating characteristics,
features and selling prices.

Technology Review

- Assessment of monoclonal antibodies, immunoassays, DNA
probes, biochips/microarrays, chromosome analysis, IT,
artificial intelligence, flow cytometry, biosensors, and their
potential applications for cancer diagnostic testing.

- Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.

- Extensive listings of over 500 companies, universities and
research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

- Extensive strategic assessments of  major suppliers
and start-up firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements and new products in R&D.

Worldwide Market Overview

- Estimated universe of laboratories performing cancer diagnostic testing
by country.

- Ten-year test volume and sales projections by country.

Business Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially
significant market appeal.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

Methodology

This report is based on interviews with clinical pathologists, laboratory directors,
executives from leading diagnostic companies and start-up firms
developing innovative products, university scientists, as well as
experts from industry associations, venture capital firms and the
investment banking community in the U.S., five major European
countries and Japan.

The market projections are also based on questionnaire
responses received from hospitals, commercial/private laboratories,
physician offices/group practices, cancer clinics and ambulatory
care centers in seven countries.

In addition to primary sources of information, a comprehensive
review of the most recent technical and business publications, manufacturer
product literature, patents, trade association surveys, government
studies, marketing and technical meeting presentations,
industry analyst reports, and VPG's proprietary data files was conducted.

Contains 1,200 pages and 450 tables

Table of Contents

Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
B. Major Current And Emerging Tumor Marker
C. Instrumentation Review And
D. Current and Emerging Technologies
E. Competing/Complementing Technologies
F. Business Environment
G. Personal Testing

France
Germany
Italy
Japan
Spain
U.K.
U.S.A.

Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
Design Criteria for Decentralized Testing Products
Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation Factor
Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

Competitive Profiles
- Abbott
- AdnaGen
- Ambrilia Biopharma
- AMDL
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CanAG Diagnostics
- CeMines
- Cepheid
- Correlogic Systems
- Dako
- Decode
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Guided Therapeutics
- Hologic
- Ipsogen
- J&J Diagnostics
- Kreatech
- Kyowa Medex
- Mackay Life Sciences
- Matritech
- Myriad Genetics
- OncoLab
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac
- Zila

Contact

Robert Fisher
Healthcare Research
robert@vpgcorp.com
+1 212 564 2838
http://www.VPGMarketResearch.com

# # #

Venture Planning Group is an international market research, publishing and management consulting firm, providing syndicated and custom services to corporate executives and key decision-makers in the Diagnostics, Pharmaceutical, Imaging, Orthopedics, Biotechnology, Chemical, Flavors & Fragrances, Food & Beverage, Electronics, and other industries.

During numerous proprietary single-client consulting assignments and over 500 multiclient studies, VPG has developed an extensive database on various industries, technologies, markets, companies, products, and executives worldwide.

VPG has served over 1,000 corporations in 70 countries, and has established a broad network of worldwide contacts with industry executives, opinion leaders, and experts from leading universities, research centers, the financial community and the government.

Specialties
Market Intelligence Surveys, Opportunity Analyses, New Technology/Product Assessments, Acquisition/Joint Venture Evaluations.